Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review

Almustafa, Zaid Z; Weller, Karsten; Autenrieth, Juliane; Maurer, Marcus; Metz, Martin

doi:10.2340/00015555-3243

Cited by 30 publications

(24 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effects of the treatment were observed across the reviewed cases suggest no difference in treatment response based on existing atopy. Efficacy of dupilumab was observed in atopic patients was similar to that in non‐atopic patients with Almustafa et al () observing a moderate effect in all three patients with a history of atopy. In addition, none of our patients had a history of atopy.…”

Section: Discussionsupporting

confidence: 67%

“…At 3 months, moderate improvement was observed; however, at 8 months, only sparse lichenified papules and some residual hyperpigmentation remained, and the patient reported a VAS score of 0.5 for pruritus compared to 9 at baseline. Almustafa et al () reported a case series of three patients with a history of atopic diseases (two with AD); the patients had chronic prurigo and all had been treated with dupilumab. In case 1, a continuous improvement was observed with a single dose of 600 mg dupilumab.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Dupilumab for prurigo nodularis: Case series and review of the literature

Holm

Agner

Sand

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin‐4 and interleukin‐13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis treated off‐label with dupilumab, and a review of the existing literature. All patients in this study had longstanding severe disease and had tried multiple treatment modalities. They were treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. Systematic literature searches were performed to identify literature describing the evaluation of the effect of treatment with dupilumab in prurigo nodularis. The physician's assessment of the patients revealed a good or excellent response to the treatment with dupilumab. Patients were evaluated after treatment for 4 and 7 months. Treatment was generally well‐tolerated; one in three patients reported dry eyes. Four studies with a total of 11 patients (range: 1–4) were identified by the literature search. Complete response was noted in all 11 patients. Treatment with dupilumab appears to be safe and well‐tolerated with clinical benefit in recalcitrant prurigo nodularis. Larger randomized and controlled trials using validated outcome measures are needed before dupilumab could be applied in clinical settings.

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Resultsmentioning

confidence: 99%

Dupilumab for prurigo nodularis: Case series and review of the literature

Holm

Agner

Sand

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Additionally, recently published case series indicate a possible role for dupilumab (a monoclonal anti‐IL‐4Rα‐antibody) in the treatment of chronic prurigo. In the four published reports with overall 11 patients with chronic prurigo treated with dupilumab, all patients showed a complete or almost complete control of pruritus . It would be interesting to learn from a placebo‐controlled trial whether this efficacy can also be seen in a larger patient population.…”

Section: What Can We Learn From Published Trials and Case Series?mentioning

confidence: 98%

Treatments for chronic pruritus outside of the box

Metz

2019

Experimental Dermatology

View full text Add to dashboard Cite

Patients with chronic pruritus are in desperate need of novel treatment options, as current therapeutic possibilities are often not effective, have a poor level of evidence and are mostly off‐label. In recent years, much effort has been put into the identification of potential targets for the treatment of chronic pruritus. More importantly, a number of promising new drugs that are aimed at treating pruritus in different conditions are currently in advanced stages of clinical trials. Here, current pharmacological developments leading to potential new drugs for the treatment of chronic pruritus within various conditions are summarized. Hopefully, these new approaches will result in effective and safe therapies for our patients with chronic pruritus associated with dermatological or non‐dermatological diseases in the near future.

show abstract

“…Eine rezente Untersuchung zeigte eine gesteigerte [9]. Im Gegensatz zu unserer Patientin war das subjektive Ansprechen (Reduktion des Pruritus) in den meisten Fällen deutlich früher zu beobachten [10][11][12][13][14]. Nur wenige dieser Patienten zeigten ein langsameres Ansprechen auf die Behandlung mit Dupilumab.…”

Section: Clinical Letterunclassified